Crescent Biopharma (CBIO) Shareholder's Equity Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.53% |
| Dec 31, 2025 | 67.85% |
| Sep 30, 2025 | 34.33% |
| Jun 30, 2025 | 35.70% |
| Mar 31, 2025 | -34.69% |
| Dec 31, 2024 | -29.86% |
| Sep 30, 2024 | -26.27% |
| Jun 30, 2024 | -43.68% |
| Mar 31, 2024 | -38.64% |
| Dec 31, 2023 | -33.09% |
| Sep 30, 2023 | -30.43% |
| Jun 30, 2023 | -27.82% |
| Mar 31, 2023 | -25.19% |
| Dec 31, 2022 | -34.70% |
| Sep 30, 2022 | -33.96% |
| Jun 30, 2022 | -32.17% |
| Mar 31, 2022 | -29.33% |
| Dec 31, 2021 | -26.49% |
| Sep 30, 2021 | -23.78% |
| Jun 30, 2021 | -21.03% |
| Mar 31, 2021 | -19.30% |
| Dec 31, 2020 | 2.32% |
| Sep 30, 2020 | 8.39% |
| Jun 30, 2020 | 8.08% |
| Mar 31, 2020 | 66.99% |
| Dec 31, 2019 | 63.47% |
| Sep 30, 2019 | 58.76% |
| Jun 30, 2019 | 54.01% |
| Mar 31, 2019 | 77.00% |
| Dec 31, 2018 | 71.87% |
| Sep 30, 2018 | 64.83% |
| Jun 30, 2018 | 60.43% |
| Mar 31, 2018 | 75.08% |
| Dec 31, 2017 | 33.07% |
| Sep 30, 2017 | 23.45% |
| Jun 30, 2017 | 21.80% |
| Mar 31, 2017 | -16.79% |
| Dec 31, 2016 | 129.84% |